Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: investor (6)

Creating value for partners through exozyme biosolutions
investorvideo
Creating value for partners through exozyme biosolutionsFebruary 12, 2025
The difference between enzymes and exozymes: Explaining our tech
investorvideo
The difference between enzymes and exozymes: Explaining our techFebruary 12, 2025
Vision: What's the potential impact of exozymes?
investorvideo
Vision: What's the potential impact of exozymes?February 12, 2025
eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
investorvideo
eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
Rebranding Invizyne to eXoZymes signifies a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
press releaseinvestor
Rebranding Invizyne to eXoZymes signifies a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne
heltzeninvestorvideo
Looking at the rest of 2025 - part 4 of a fireside chat about InvizyneFebruary 11, 2025
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
press releaseinvestor
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker SymbolFebruary 10, 2025
ARCHIVE: CEO buys IZTC stock
investorARCHIVE
ARCHIVE: CEO buys IZTC stockJanuary 21, 2025
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about InvizyneJanuary 15, 2025
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About InvizyneJanuary 7, 2025
Previous page
Page 6 of 8
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark